Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Immunotherapies targeting the PD-1/PD-L1 axis are now a mainstay in the clinical management of multiple cancer types, however, many tumors still fail to respond. CCL2 is highly expressed in various cancer types and has been shown to be associated with poor prognosis. Inhibition or blockade of the CC...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Megan M., Abdel-Hafiz, Hany A., Jones, Robert T., Jean, Annie, Hoff, Katelyn J., Duex, Jason E., Chauca-Diaz, Ana, Costello, James C., Dancik, Garrett M., Tamburini, Beth A. Jirón, Czerniak, Bogdan, Kaye, Jonathan, Theodorescu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699641/
https://www.ncbi.nlm.nih.gov/pubmed/33247183
http://dx.doi.org/10.1038/s42003-020-01441-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699641/
https://www.ncbi.nlm.nih.gov/pubmed/33247183
http://dx.doi.org/10.1038/s42003-020-01441-y

Ejemplares similares